Related Experiment Videos
Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.
E J Murphy1, T J Davern, A O Shakil
1Department of Medicine, University of California, San Francisco, 94143-0538, USA.
Digestive Diseases and Sciences
|April 5, 2000
Summary
Troglitazone can cause irreversible liver injury, necessitating cautious use in type II diabetes mellitus (DM). Alternative treatments are preferred due to potential hepatotoxicity risks.
Area of Science:
- Hepatology
- Pharmacology
- Endocrinology
Background:
- Troglitazone, a medication for type II diabetes mellitus (DM), has been associated with liver injury.
- Understanding the idiosyncratic nature of troglitazone-induced hepatotoxicity is crucial for patient safety.
Observation:
- Three cases revealed troglitazone as an idiosyncratic hepatotoxin causing irreversible liver damage.
- The onset of liver injury is insidious and variable, complicating monitoring.
Findings:
- Troglitazone poses a significant risk of severe liver injury.
- Monitoring serum aminotransferases and symptoms is mandatory but its effectiveness is uncertain.
Implications:
- Troglitazone should not be a first-line treatment for type II DM.
- Further research is needed to determine if hepatotoxicity is drug-class specific or unique to troglitazone.
- Alternative thiazolidinediones may offer therapeutic benefits without similar risks.